Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?

Overview of attention for article published in Frontiers in oncology, October 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 24,480 followers.

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival? https://t.co/MoWbQxvZ9v https://t.co/QSxu8xGXJ2

03 Nov 2022

Reply Repost Favourite

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?: Background Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic… #oncology https://t.co/jq

26 Oct 2022

Reply Repost Favourite

New research: Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?: Background Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic… https://t.c

26 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.